(Received for publication 13 June 1968) We have shown previously that phenylbutazone and sulfinpyrazone inhibit the response of platelets to particulate matter and surfaces, and that this is associated with impairment of hemostasis and prolongation of platelet survival (2, 3) . Since the pyrazole compounds have anti-inflammatory properties, it seemed possible that other anti-inflammatory compounds might have similar effects on platelets.
Acetylsalicylic acid (aspirin) is associated with hemorrhagic episodes in man. Beaumont and Willie (4) found that it caused a prolongation of the bleeding time in adults with cardiac diseases. Recently it has been shown that the administration of acetylsaUcylic acid to subjects with hemorrhagic disorders also causes a considerable prolongation of the bleeding time (5) , and Gast (6) has reported that it caused a decrease in platelet-stickiness. Bounameaux and van Cauwenberge (7) demonstrated in rats that administration of sodium salicylate also decreased platelet adherence to glass. Weiss and Aledort (8) have reported that aspirin inhibits collagen-induced platelet aggregation, and we have shown that inhibition of the platelet-collagen reaction impairs hemostasis (3) . In this paper some effects of acetylsalicylic acid on platelet function in vitro and in vivo are described.
Materials and Methods
Tyrode's Solutions.--Tyrode's solution was prepared as specified by Parker (9) . Modified tryptamine-3'-14C-creatinine sulfate (14C-5-HT) (Radiochemical Centre, Amersham, England). 14C-5-HT was added to EDTA platelet-rich plasma and allowed to incubate for 30 rain at 37°C. The platelet-rich plasma was then centrifuged at 650 g for 15 rain at 4°C. Suspensions of washed platelets were prepared as described above for studies of the release of 14C-serotonin.
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Release of AMP, ADP, and 14C-Serotonin.--i ml of platelet suspension was mixed with 0.1 ml of a solution of axzetylsalicylic acid (diluted to the desired concentration with modified Tyrode's solution). In the control experiments, 0.1 ml of modified Tyrode's solution was substituted for the solution of acetylsalicylic acid. In order to induce platelet aggregation and release platelet constituents, 0.1 ml of a suspension either of collagen, antigen-antibody complexes, gamma globulln--coated polystyrene, or a thrombin solution was added, and the mixture was agitated constantly for 10 min at 37°C. The concentrations of ADP and AMP in the platelets and in the ambient fluid were determined, and the amounts of 14C in the ambient fluid and platelets measured by methods reported elsewhere (3, 11) .
Whole Blood Clotting Time; One-Stage Protkrombin Time; Partial Tkromboptastin Time.--
These studies were carried out with whole blood, or plasma prepared from blood taken into citrate, by methods given in detail in eaxlier publications (13, 14) .
Tkrombin Clotting Time.--Freeze-dried human fibrinogen (Connaught Medical Research
Laboratories) was dissolved in distilled water (0.5 g/100 ml) and dialyzed against 0.85% NaCI for 12 hr at room temperature. The fibrinogen solution was adsorbed with aluminum hydroxide (moist gel, British Drug Houses), 1 part AI (OH)3 to 5 parts fibrinogen solution, incubated at 37°C for 10 rain, centrifuged at 4000 g for 15 rain). To 0.2 ml of the fibrinogen solution was added 0.2 ml of ~s/40 CaCI2, 0.1 ml of the ASA solution, and 0.2 ml of the thrombin solution. The clotting time of the fibrinogen solution after addition of the thrombin was determined at 37°C.
Hemostasis.--The technique for evaluation of hemostasis by cutting small mesenteric vessels has been described (15) . In these experiments, the acetylsalicylic acid was given orally to animals starved for 12 hr. The duration of time from the onset of bleeding to its arrest was recorded by direct observation of the vessel. The total duration of any renewed bleeding was also observed during the 30 rain following transection of the vessel.
Statistical Considerations (16) .--The studies on hemostasis were done on 72 animals which were randomly assigned to 12 groups of 6 each. On each of 4 days, three groups were studied; one group acting as controls, one receiving 100 mg/kg of ASA, and one 200 mg/kg. Thus there are four possible sources of variation in the results:
1. There may be a variation attributable to differences produced by treatment with aspirin. This will be referred to as the dosage effect. Since there are three dosage levels, there are 3-1 = 2 degrees of freedom associated with it. This source of variation may in turn be partitioned into a linear component (which implies a proportionality between prolongation of bleeding time and dosage) and a quadratic component (which implies that there is a prolongation related to the square of dosage). The complete experiment explores the model
Yl = a + bxi + cx] + ei
where xl is a particular dosage, Yl the bleeding time, ~i a random error and a, b, and c constants. If c=0, there is a simple linear relationship; iS c=b=0, effect is quite unrelated to dosage. The tests whether e and b are zero are orthogonal, i.e. statistically independent, and one of the degrees of freedom is associated with each.
2. There may be variation attributable to difference in days caused by a variety of unspecified causes. This is denoted by "day effect." With it are associated 4--1=3 degrees of freedom.
3. While on each day the bleeding time may be affected by dosage, that is in the above equation either b or c or both are non-zero, the values b and c take may vary from day to day. This component of variance is designated "interaction." There are (3--1) (4--1) = 6 degrees of freedom associated with it. A significant interaction would indicate that on some days, the drug has more effect than on others.
4. Even under identical conditions and on the same dosage, animals differ in their responses to treatment. This source of variation is termed "error." For each of the 12 groups of 6, one parameter (the mean) is estimated and therefore one degree of freedom lost. Thus in all there are 12 X (6-1) = 60 error degrees of freedom. For the purposes of this experiment, the error mean square is created as the irreducible component of variation and provides the denominator for all F tests. However, if the interaction mean square is significantly greater than the error mean square, principal effects (days and dosage) should be tested not against error but against interaction. The resulting F tests will therefore have 6 rather than 60 degrees of freedom associated with their denominators.
Platelet Survival S~ties on Rabbits.--These were carried out by a modification (2, 17) of the method of Leeksma and Cohen (18) . Acetylsaiicylic acid-treated rabbits were given the drug twice daily in doses ranging from 50-400 mg/kg per day. The control animals received placebo tablets. On the 4th day of this regimen, the animals received intravenously diisopropyl-(1,3-'£) phosphorofluoridate (in sterile solution) (~-I-DFP) obtained from the Radiochemical Center. The specific activity of the labeled DFP was 2000/~c/mg and each rabbit received 50 #c. The dose of labeled DFP was therefore less than 0.01 mg/kg body weight. The rabbits were bled daily for 7 days from ear veins into plastic syringes containing 2% EDTAsaline. Platelets from each 10 ml blood sample were isolated and their radioactivities measured. The platelets were separated (2), put on a small piece of taxed aluminum foil, dried, and weighed. The dried platelets were then placed in a counting vial to which 0.25 ml NCS (Nuclear-Chicago Corp., Des Plaines, Ill.) was added. 12 hours later a toluene-fluor solution (PPO, POPOP) was added and the radioactivity measured in a liquid scintillation counter. The radioactivity is expressed as cpm/mg dried platelets. The platelet half-life value for each animal was calculated by the iterative, nonlinear, unweighted least squares method (19) . Platelet turnover (in platelets/mm s per day) was calculated as: 0.693 X average number of platelets per mm 3
Half-life in days
Assay of Aeetylsalicylic Acid in Plasma.--This was carried out by the method of Trinder (20) (Extraction of plasma from untreated animals gave a variable blank value between 1 and 3 mg per 100 ml of plasma.)
Extracorporeal Shunts.--The design of the shunt used has been specified in detail (2) . In these experiments, ASA was given intravenously to rabbits at a dosage of 200 mg/kg body weight over a period of 10 rain. Control animals were given modified Tyrode's solution. Blood flow through the extraeorporeal shunts was begun 30 rain after the intravenous infusion and continued for 20 rain.
In these experiments, the bifurcation of the shunt was coated with gamma globulin (3). The bifurcation was filled with the solution, emptied, and rinsed three times with modified Tyrode's solution prior to its insertion into the shunt.
A Note on Transformatiom.--To meet more closely the assumptions underlying analysis of variance (principally that the error terms be normally distributed and have a uniform variance), it is sometimes desirable to use not the measurments in their natural state hut to take some mathematical function of these, such as the logarithms. This procedure, while not destroying the information in the values, modifies it somewhat. It should be regarded as a simple computational device which may or may not have an interpretable biological meaning. It is convenient in expressing means or confidence limits to convert them back to the original system of measurement.
R E S U L T S
In Vitro St~ies.--The addition of acetylsalicylic acid (ASA) to citrated human PRP suppressed platelet aggregation induced by collagen but did not influence aggregation induced by ADP (Fig. 1) . Similar results were observed with pig and rabbit PRP. Shown in Fig. 2 is the effect of different concentrations of ASA on platelet aggregation induced by collagen. Acetylsalicylic acid also inhibited thrombin-induced platelet aggregation in human and rabbit citrated PRP (Fig. 3 ). This effect was demonstrable only with the minimum doses required to produce platelet aggregation. Because the high concentration of thrombin necessary to induce platelet aggregation in citrated pig PRP caused the rapid onset of fibrin formation, it was not possible to study the effect of acetylsalicylic acid on thrombin-induced platelet aggregation in pig plasma.
To examine the influence of this drug in a system in which the effects of antigen-antibody complexes and gamma globulin-coated surfaces could be explored, we used suspensions of washed human, pig, or rabbit platelets. Acetylsalicylic acid inhibited the action of collagen, antigen-antibody complexes, and gamma globulin-coated polystyrene in inducing platelet aggregation in these suspensions (Fig. 4) . In the washed platelet suspension, the effect of thrombin in low concentrations was also inhibited by acetylsalicylic acid (Fig. 5) . However, although ASA inhibited thrombin-induced platelet aggregation, it did not inhibit the clotting of fibrinogen by thrombin (Table I) . It is known that thrombin, collagen, antigen-antibody complexes, and gamma globulin-coated surfaces cause the release of platelet constituents such as serotonin, ADP, and AMP into the ambient fluid. Accordingly, we examined the effect of ASA on the release of these compounds from pig platelets. The addition of ASA to a platelet suspension reduced the amount of ADP and AMP released by a collagen suspension (Table II) .
Pig platelets were labeled in vitro with 14C-serotonin. In the presence of ASA, they released less radioactivity into the ambient fluid when they were (Table III) . The effect of low concentrations of thrombin on the release of platelet constituents from a suspension of washed pig platelets was inhibited by acetylsalicylic acid (Table IV) . Sodium salicylate was also found to suppress platelet aggregation induced by collagen and low concentrations of thrombin but did not affect ADPinduced platelet aggregation in citrated PRP. The addition of sodium salicylate to a suspension of washed 14C-serotonln-labeled pig platelets inhibited the release of radioactivity and nucleofides induced by collagen, antigen-antibody complexes, and gamma globulin-coated polystyrene (Table V) .
In Vivo Studies.--Four aspects of the in vivo effects of acetylsalicylic acid were studied in rabbits: the suppression of collagen-induced platelet aggregation following oral administration of the drug, the effects of oral administration on hemostasis, the effect of the drug on platelet survival, and the effect of intra- venous administration of the drug on the formation of deposits in the bifurcation of an extracorporeal shunt.
The effect of in vivo administration of acetylsalicylic acid: Platelet aggregation in vitro in citrated PRP prepared from blood taken from rabbits before and 30 rain after the intravenous infusion of ASA (200 mg/kg) was similar to that seen in the in vitro experiments. The response of the platelets in citrated plateletrich plasma to collagen and thrombin, but not to ADP, was suppressed after the infusion compared with the preinfusion response.
ACETYLSALICYLIC ACID AND PLATELET FUNCTION
Collagen-induced platelet aggregation was studied 2 hr after the oral administration of ASA to rabbits at different dosage levels (100 mg/kg of ASA produced a plasma level of 38 rag/100 ml). Aggregation induced by this stimulus was inhibited (Table VI) . In these experiments, the oral administration of ASA had no detectable effect on the platelet count, the whole blood-clotting time in glass and silicone-coated tubes, the one-stage prothrombin time, or the partial thromboplastin time (Table VII) . * 0.1 ml added to 1.1 ml of platelet suspension containing acetylsalicylic acid.
The effect on hemostasis: Acetylsallcylic acid was given orally to rabbits in the dosage of 100 or 200 mg/kg. It can be seen (Table VIII and IX) that, upon transection of the mesenteric vessels 2 hr after administration of the drug, hemostasis was impaired. The rabbits given ASA showed a considerable lengthening of the time taken for the formation of a platelet plug capable of arresting hemorrhage. There was considerable renewed bleeding through the platelet plugs indicating that they were unstable. The total time of bleeding represents the combined time for primary arrest and the duration of the renewed bleeding. In comparison, control animals showed little renewed hemorrhage through the plugs and the total time of bleeding rarely exceeded 5 min. The extent of the prolongation is dose dependent. Over the dosage range used in these experiments, the relationship appears to be linear. No significant quadratic component was demonstrated. While the effect was consistent in the few days of study, the regression slope of prolongation on dosage varied appreciably from day to day. This is reflected in the interaction term in the analysis of variance which exceeds the error term to a highly significant extent. Accordingly, as has been noted above, the effect of dosage has to be tested against the interaction mean square rather than that for error.
ACF.TYLSALICYLIC ACID AND PLATELET ~UNCTION
The effect on platetet survival: Platelet survival studies were done on rabbits receiving, orally, various doses of acetylsalicylic acid (Table X) . Control animals were given placebo tablets. On the 4th day of the regimen the animals were injected with aH-DFP, platelets were isolated daily thereafter for 7 days and their radioactivity measured. Platelet survival follows a normal distribution curve sufficiently closely for accurate analysis (21) . In a previous paper (2), however, it was noted that the standard deviation of mean survival is sometimes proportional to the mean, a relationship which is abolished if the logarithms of the values are used. This relationship was evident in the present study and to stabilize the variance a logarithmic transformation was used on the individual estimates of the means before the regression line on dosage was fitted. In spite of some irregularity in results which may be due to the small size of some of the treatment groups, there is considerable increase in mean survival with increasing ASA intake, and this is significant at the 1 in 100 level. There is a corresponding decrease in platelet turnover. Since the variance for this value was naturally stable, no logarithmic transformation was required.
Formation of deposits of blood materials in the bifurcation of extracorporeal shunts:
We have reported earlier (22) that by using the logarithms of the weights of the deposits, the distribution of the weights is normalized and the variance which is ordinarily closely related to the mean is stabilized. All the calculations are therefore carried out on the logarithms of the dry weights of deposits but mean values have been converted back into the original scale for display in Table XI . These values are accordingly geometric means. It can be seen that administration of acetylsalicylic acid (200 mg/kg) intravenously 30 min before blood flow was started in the shunt produced a significant diminution in the amount of deposit on a bifurcation coated with gamma globulin. There was no significant difference in mean rates of flow between the two groups of animals. The results from this study show that ASA inhibits platelet aggregation in citrated PRP or in suspensions of washed platelets induced by collagen, antigenantibody complexes, or gamma globulin-coated polystyrene, but does not inhibit aggregation induced by ADP. In addition, ASA inhibits platelet aggregation induced by small doses of thrombin. There is evidence that thrombin and particulate stimuli cause platelet aggregation by releasing ADP from platelets (23) . Since doses of ASA which inhibited platelet aggregation induced by thrombin or by the particulate stimuli also inhibited the release of platelet constituents, it seems likely that the effect of ASA on platelet aggregation can be 890
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attributed to inhibition of the release of platelet ADP. Weiss and Aledort (8) have come to a similar conclusion concerning the effect of ASA in inhibiting collagen-induced platelet aggregation. We originally thought that ASA did not influence thrombin-induced platelet aggregation (1, 24) but we have subsequently found that ASA will inhibit thrombin-induced platelet aggregation N.B. To stabilize the variance the transformation Y = log (X + 600) is used where X is the number of seconds. The figures in the analysis of variance refer to this transformation. However, the mean values calculated from this transformation have been converted back into the original scale by the reverse process, i.e., X = antilog (Y) --600. The mean values given above are in this form. * There were 6 animals in each group for each study.
if the concentration of thrombin used is adjusted to that which will just produce platelet aggregation. In earlier studies (3), we similarly failed to demonstrate an effect of the pyrazole compounds on thrombin-induced platelet aggregation, because the concentration of thrombin used was too high (25) . 1 ASA is converted to sodium salicylate in vivo, and our in vitro results indicate that sodium salicylate also is effective in inhibiting platelet aggregation induced 1 Packham, M. A., and J. F. Mustard. Unpublished observations. by the particulate stimuli, probably by the same mechanism of reducing the extent of the release of platelet constituents. There is evidence from other studies (7, 26) that sodium salicylate decreases platelet stickiness and interferes with hemostasis. The results from the in vivo experiments substantiate the in vitro studies. The concentrations of ASA necessary to inhibit platelet aggregation were of the same magnitude as those in the in vitro studies.
There is considerable evidence (15) that the exposed connective tissue at the end of a transected vessel provides a stimulus for the formation of a platelet mass. In the present experiments, the administration of ASA in doses which inhibited collagen-induced platelet aggregation caused defective hemostasis 892 ACETYLSALICYLIC ACID AND PLATELET I~UNCTION manifested by a delay in the primary arrest of bleeding and by increased susceptibility to breakdown of the platelet plug with renewed bleeding through it. The action of ASA on hemostasis could be due to its effects on collagen and thrombin-induced platelet aggregation. Since in the acute experiments, ASA did not affect blood coagulation, and we could show no effect of ASA on the conversion of fibrinogen to fibrin by thrombin, it seems reasonable to attribute the hemostatic defect to inhibition of platelet aggregation.
The function of the platelet is important in determining its survival (2, 3, 25) . The results from this study indicate that ASA prolongs platelet survival. Since the interaction of platelets with stimuli such as collagen, antigen-antibody complexes, or viruses can induce the release of platelet constituents and cause aggregation, it is possible that ASA increases platelet survival by suppressing the response of platelets to such stimuli.
In the experiments with the extracorporeal shunts we used surfaces which had been exposed to gamma globulin. This provided a surface which, in vitro, produced adherence of platelets to the surface and to each other with extensive release of ADP (3) . When the bifurcation is coated with gamma globulin it produces more than four times the deposit found in an uncoated bifurcation (27) . The results of the present experiments show that ASA produces a significant diminution in the amount of material deposited when blood flows past such a surface. 1:894) has shown that the oral administration of acetylsalicylic acid to human subjects suppressed the secondary response of these platelets to adrenaline and ADP as well as inhibiting the effect of collagen. He did not find any effect on thrombin-induced platelet aggregation.
SITM:M.ARY
Acetylsalicylie acid (ASA, aspirin) and sodium salicylate inhibit platelet aggregation induced by collagen, antigen-antibody complexes, gamma globulincoated particles or thrombin. These compounds suppress the release of platelet constituents, such as adenosine diphosphate (ADP) and serotonin, induced by such stimuli. Since ASA and sodium salicylate do not inhibit ADP-induced platelet aggregation, it appears that their effect on the action of the other stimuli is due to a decrease in the amount of ADP released. The administration of ASA to rabbits (in doses which inhibited collagen-induced platelet aggregation) impaired hemostasis, prolonged platelet survival, and diminished the amount of deposit formed in an extracorporeal shunt.
